文献速递淋巴瘤

Myc对EPOCH治疗HIV相关非霍奇金淋巴瘤的影响及伏立诺他的结局(AMC-075试验)

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).
PubMed 文献 · Blood · 2020-01-01

这项随机2期研究纳入90例侵袭性HIV相关非霍奇金淋巴瘤患者,比较剂量调整EPOCH方案联合或不联合伏立诺他(300 mg,每周期第1至5天给药)的疗效。86例可评估患者中,完全缓解率EPOCH组为74%,EPOCH-伏立诺他组为68%(P=0.72)。伏立诺他未清除HIV储存库,且4级中性粒细胞减少和血小板减少更频繁,未影响生存。Myc阳性弥漫大B细胞淋巴瘤、低CD4计数和低诊断至治疗间隔与较差结局相关。

要点

  • EPOCH方案对高度侵袭性HIV相关非霍奇金淋巴瘤具有广泛疗效。
  • 伏立诺他联合EPOCH未改善完全缓解率,且增加4级血液学毒性。
  • Myc阳性弥漫大B细胞淋巴瘤、低CD4计数和低诊断至治疗间隔提示预后较差。

核心结论

  • EPOCH方案对高度侵袭性HIV相关非霍奇金淋巴瘤具有广泛疗效,而伏立诺他没有获益。
  • Myc驱动的弥漫大B细胞淋巴瘤、低CD4计数和低诊断至治疗间隔的患者结局较差。
  • 允许方案前治疗可促进入组且不损害结局。

研究设计与样本

  • 随机2期研究,共纳入90例侵袭性HIV相关非霍奇金淋巴瘤患者,每组45例。
  • 治疗方案为剂量调整EPOCH方案(CD20阳性者加用利妥昔单抗),联合或不联合伏立诺他300 mg(每周期第1至5天给药)。
  • 允许最多1个既往全身化疗周期。
  • 主要终点为完全缓解(CR)。
  • 试验注册号为NCT0119384。

主要发现

  • 86例可评估患者包括弥漫大B细胞淋巴瘤61例、浆母细胞淋巴瘤15例、原发性渗出性淋巴瘤7例、不可分类B细胞非霍奇金淋巴瘤2例和伯基特淋巴瘤1例。
  • 完全缓解率EPOCH组为74%,EPOCH-伏立诺他组为68%(P=0.72)。
  • CD4+计数<200 cells/mm3的患者完全缓解率较低。
  • EPOCH-伏立诺他未清除HIV储存库,4级中性粒细胞减少和血小板减少更频繁,未影响生存。
  • Myc阳性弥漫大B细胞淋巴瘤患者无事件生存期(EFS)显著较低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) is a preferred regimen for HIV-non-Hodgkin lymphomas (HIV-NHLs), which are frequently Epstein-Barr virus (EBV) positive or human herpesvirus type-8 (HHV-8) positive. The histone deacetylase (HDAC) inhibitor vorinostat disrupts EBV/HHV-8 latency, enhances chemotherapy-induced cell death, and may clear HIV reservoirs. We performed a randomized phase 2 study in 90 patients (45 per study arm) with aggressive HIV-NHLs, using dose-adjusted EPOCH (plus rituximab if CD20+), alone or with 300 mg vorinostat, administered on days 1 to 5 of each cycle. Up to 1 prior cycle of systemic chemotherapy was allowed. The primary end point was complete response (CR). In 86 evaluable patients with diffuse large B-cell lymphoma (DLBCL; n = 61), plasmablastic lymphoma (n = 15), primary effusion lymphoma (n = 7), unclassifiable B-cell NHL (n = 2), and Burkitt lymphoma (n = 1), CR rates were 74% vs 68% for EPOCH vs EPOCH-vorinostat (P = .72). Patients with a CD4+ count <200 cells/mm3 had a lower CR rate. EPOCH-vorinostat did not eliminate HIV reservoirs, resulted in more frequent grade 4 neutropenia and thrombocytopenia, and did not affect survival. Overall, patients with Myc+ DLBCL had a significantly lower EFS. A low diagnosis-to-treatment interval (DTI) was also associated with inferior outcomes, whereas preprotocol therapy had no negative impact. In summary, EPOCH had broad efficacy against highly aggressive HIV-NHLs, whereas vorinostat had no benefit; patients with Myc-driven DLBCL, low CD4, and low DTI had less favorable outcomes. Permitting preprotocol therapy facilitated accruals without compromising outcomes. This trial was registered at www.clinicaltrials.gov as #NCT0119384.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ramos JC, Sparano JA, Chadburn A, et al. Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood. 2020. PMID: 32430507. doi:10.1182/blood.2019003959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。